Regeneron Pharmaceuticals (REGN) EBT (2016 - 2025)
Historic EBT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $1.0 billion.
- Regeneron Pharmaceuticals' EBT rose 893.43% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 billion, marking a year-over-year increase of 943.12%. This contributed to the annual value of $5.2 billion for FY2025, which is 943.12% up from last year.
- Latest data reveals that Regeneron Pharmaceuticals reported EBT of $1.0 billion as of Q4 2025, which was up 893.43% from $1.8 billion recorded in Q3 2025.
- In the past 5 years, Regeneron Pharmaceuticals' EBT registered a high of $3.8 billion during Q2 2021, and its lowest value of $700.7 million during Q1 2024.
- Over the past 5 years, Regeneron Pharmaceuticals' median EBT value was $1.2 billion (recorded in 2021), while the average stood at $1.4 billion.
- Per our database at Business Quant, Regeneron Pharmaceuticals' EBT skyrocketed by 30840.13% in 2021 and then tumbled by 7433.38% in 2022.
- Regeneron Pharmaceuticals' EBT (Quarter) stood at $2.5 billion in 2021, then plummeted by 47.08% to $1.3 billion in 2022, then dropped by 13.37% to $1.1 billion in 2023, then dropped by 16.51% to $958.1 million in 2024, then grew by 8.93% to $1.0 billion in 2025.
- Its EBT was $1.0 billion in Q4 2025, compared to $1.8 billion in Q3 2025 and $1.5 billion in Q2 2025.